Skip to content

Public FDA record

Z-2749-2016: Pacemakers: Accolade MRI DR Model L311; Accolade MRI DR EL Model L331; and Essentio MRI DR Model L111.

Recall record Z-2749-2016 for Boston Scientific Corporation. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2749-2016
Company in FDA record
Boston Scientific Corporation
FDA classification date
Sep 7, 2016
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Five Accolate MRI and Essentio MRI DR pulse generators with an alternate MICS module configuration were shipped to US customers and implanted. This alternate configuration did not receive FDA approval yet.

Source facts

Action
As we considered the value of a direct physician communication we have not identified any information that would be of value to the physician because device performance and behavior remain unchanged.
Initiated
2016-06-15
Root cause
Process control
Terminated
2017-02-06
Distribution
Distributed to the states of TX, NH, MA, PA, and MN.
Recall number
Z-2749-2016
Recall status
Terminated
CDRH record ID
148506
FDA classified
2016-09-07
Recall event number
74812

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗